COVID-19, Long COVID, and Erectile Dysfunction

John Murphy, CEO The COVID-19 Long haul Foundation

Abstract

Erectile dysfunction (ED) is increasingly recognized as a potential genitourinary manifestation of coronavirus disease 2019 (COVID-19) and its post-acute sequelae. The association is biologically plausible because penile erection depends upon an integrated vascular, endothelial, neural, autonomic, endocrine, and psychological system, all of which may be disturbed by SARS-CoV-2 infection. Epidemiological studies have reported an increased incidence of newly diagnosed ED following COVID-19, while clinical investigations of men with persistent post-COVID symptoms have documented endothelial dysfunction, autonomic abnormalities, hypogonadal states, and, in a small number of patients, evidence of SARS-CoV-2 RNA within penile tissue.

The most compelling mechanistic evidence concerns endothelial dysfunction. Penile erection is fundamentally a neurovascular event in which parasympathetic signaling, nitric-oxide release, cyclic guanosine monophosphate signaling, cavernosal smooth-muscle relaxation, and adequate arterial inflow must operate in concert. SARS-CoV-2-associated endothelial injury, inflammation, oxidative stress, impaired nitric-oxide bioavailability, vascular dysregulation, and potentially persistent tissue viral material could therefore impair erectile physiology. Additional mechanisms include autonomic neuropathy, small-fiber dysfunction, hypogonadism, systemic inflammation, cardiopulmonary limitation, metabolic deterioration, medication effects, depression, anxiety, sleep disturbance, and the psychological consequences of severe illness.

A 2026 systematic review and meta-analysis of nine studies involving 2,332 participants estimated a pooled erectile-dysfunction frequency of 21% among individuals with Long COVID, although substantial heterogeneity and differences in ascertainment limit interpretation. Earlier large electronic-health-record analyses also identified an association between COVID-19 and newly diagnosed ED after adjustment for major vascular and metabolic confounders. Conversely, the literature does not establish that SARS-CoV-2 is responsible for all erectile dysfunction occurring after infection. Age, diabetes, hypertension, obesity, cardiovascular disease, renal disease, medications, depression, and pre-existing endothelial dysfunction remain major alternative or interacting explanations.

Management should therefore follow established principles of sexual medicine while addressing potentially reversible post-COVID contributors. Evaluation should include cardiovascular and metabolic risk assessment, medication review, morning testosterone testing when clinically appropriate, and assessment for autonomic or neurological disease when indicated. Phosphodiesterase type-5 inhibitors remain first-line pharmacological therapy for most men without contraindications. Vacuum erection devices, intracavernosal therapy, intraurethral therapy, penile prosthesis implantation, and psychosexual interventions provide additional options when oral therapy fails. Testosterone replacement should be reserved for men with documented hypogonadism and appropriate clinical indications rather than used empirically for post-COVID ED.

The prognosis is heterogeneous. Some men improve as endothelial, autonomic, endocrine, and systemic abnormalities resolve; others develop persistent dysfunction requiring conventional long-term ED treatment. Increasing evidence supports viewing erectile dysfunction in selected Long COVID patients not merely as an isolated sexual symptom but potentially as a marker of broader vascular, autonomic, metabolic, or systemic disease.

Introduction

Erectile dysfunction is defined clinically as the persistent inability to attain or maintain an erection sufficient for satisfactory sexual performance. Although frequently conceptualized as a localized genital disorder, erectile function is an integrated physiological endpoint requiring intact arterial inflow, endothelial signaling, cavernosal smooth-muscle relaxation, venous occlusion, autonomic and somatic neural function, adequate androgenic activity, and appropriate psychological and relational conditions.

COVID-19 is capable of perturbing virtually every component of this system.

The emergence of ED as a potential complication of SARS-CoV-2 infection is therefore not surprising from a physiological standpoint. The initial pandemic literature emphasized pulmonary disease, thrombosis, myocarditis, renal injury, and neurological complications. As survivorship increased, however, persistent disturbances of sexual function became increasingly apparent. A 2022 review characterized erectile dysfunction as a potentially important manifestation of what the authors termed “sexual Long COVID,” emphasizing the convergence of endothelial dysfunction, cardiovascular disease, hypogonadism, psychological stress, and neurological abnormalities.

The question is no longer simply whether ED can occur following COVID-19. The more important questions are:

How frequently does it occur?
Does SARS-CoV-2 independently increase the risk?
What mechanisms are responsible?
Which patients are most vulnerable?
Is the dysfunction reversible?
What treatments are effective?

The evidence increasingly suggests that the answer to all five questions is complex.

Epidemiology of Erectile Dysfunction After COVID-19

The epidemiological literature has consistently suggested an association between COVID-19 and subsequent ED.

One large U.S. electronic-health-record study used the TriNetX Research Network, containing data from more than 42 health-care organizations and approximately 66 million patients. Men with documented COVID-19 were compared with matched men without COVID-19 after exclusion of pre-existing ED and adjustment for age, race, body-mass index, diabetes, hypertension, ischemic heart disease, and hyperlipidemia. The investigators reported an association between COVID-19 infection and subsequent new diagnosis of ED.

Such an analysis is important because many of the variables that predispose to ED—particularly diabetes, obesity, hypertension, vascular disease, and advancing age—also predispose to severe COVID-19. Adjustment for these factors reduces, although does not eliminate, the possibility that the association merely reflects conventional vascular risk.

More recent evidence is provided by a 2026 systematic review and meta-analysis examining the genitourinary phenotype of Long COVID. Nine studies comprising 2,332 participants were included. The pooled frequency of ED among Long COVID patients was estimated at 21% (95% CI, 16–28%). In subgroup analysis, the frequency was approximately 19% among patients with moderate disease and 25% among those with severe disease, although the difference was not statistically significant.

This estimate should not be interpreted as a population prevalence of COVID-induced impotence. The included studies differed in patient selection, disease severity, definitions of Long COVID, methods of assessing ED, and follow-up intervals. Nevertheless, the convergence of multiple observational studies supports ED as a clinically relevant component of post-COVID morbidity.

Erectile Function as a Vascular Phenotype

The vascular basis of erection provides a particularly compelling explanation for the association.

Penile erection depends upon increased parasympathetic neural activity and release of nitric oxide (NO) from endothelial and neuronal sources. NO activates soluble guanylate cyclase within cavernosal smooth muscle, increasing cyclic guanosine monophosphate (cGMP), reducing intracellular calcium, and producing smooth-muscle relaxation. Increased arterial inflow expands the corpora cavernosa, while compression of subtunical venous channels produces veno-occlusion and maintenance of rigidity.

Endothelial dysfunction can disrupt this process at several levels.

SARS-CoV-2 infection has been associated with endothelial activation, inflammation, oxidative stress, altered vascular tone, and impaired NO signaling. Because the penile circulation is highly dependent upon endothelial NO-mediated vasodilation, even modest endothelial dysfunction can manifest clinically as impaired erection.

The relationship is therefore physiologically coherent:

SARS-CoV-2 infection → endothelial injury/dysfunction → reduced NO bioavailability → impaired cavernosal relaxation → impaired arterial inflow and veno-occlusion → erectile dysfunction.

This pathway is not merely theoretical.

Direct Evidence From Penile Tissue

One of the most striking observations in the COVID-19/ED literature derives from a small histopathological investigation of penile tissue.

Researchers examined corpus cavernosum specimens from four men undergoing penile prosthesis surgery for severe ED. Two had previously experienced COVID-19 and two had not. SARS-CoV-2 RNA was detected in penile tissue from the two previously infected patients but not in the controls. Electron microscopy identified coronavirus-like particles near penile vascular endothelial cells. Furthermore, endothelial nitric oxide synthase (eNOS) expression was reduced in the COVID-19 specimens, suggesting impaired endothelial function.

These observations are potentially important because they provide a biological link between SARS-CoV-2 infection and erectile physiology at the level of the erectile organ itself.

However, scientific caution is essential.

The study involved only two COVID-positive patients. Both already had severe ED requiring penile prostheses, and the investigation was not designed to establish prevalence or causality. Detection of viral RNA also does not prove that replication-competent virus persisted in the penis or that viral material directly caused the ED.

The correct interpretation is therefore:

The study provides evidence compatible with direct or persistent SARS-CoV-2-related penile endothelial involvement, but it does not establish that persistent penile infection is the usual mechanism of post-COVID ED.

This distinction is critical.

Endothelial Dysfunction and Nitric Oxide

The penile vascular bed may be particularly sensitive to systemic endothelial injury because erection depends on rapid, profound vasodilation.

COVID-19 can theoretically impair this system through several mechanisms:

Reduced nitric-oxide bioavailability

Inflammation and oxidative stress can increase reactive oxygen species, which react with NO and reduce its biological availability.

Endothelial inflammation

Activated endothelial cells may express adhesion molecules, release inflammatory mediators, and lose normal vasodilatory properties.

Microvascular dysfunction

Even without large-vessel thrombosis, impaired microvascular perfusion can interfere with cavernosal oxygenation and smooth-muscle function.

Vascular remodeling

Persistent endothelial injury can promote vascular stiffness and impaired responsiveness.

Thrombo-inflammatory mechanisms

COVID-19 is associated with activation of coagulation and inflammatory pathways. Although the contribution of microthrombotic processes specifically to ED remains uncertain, such mechanisms are biologically plausible.

These processes overlap substantially with conventional cardiovascular mechanisms of ED.

Indeed, ED is itself recognized as an early clinical manifestation of systemic endothelial and cardiovascular disease. COVID-19 may therefore accelerate or expose a vascular vulnerability that was previously clinically silent.

Neurogenic and Autonomic Mechanisms

An erection is also a neurological event.

Parasympathetic pathways arising from sacral spinal segments, peripheral autonomic nerves, pelvic nerves, sensory afferents, and central neural circuits collectively participate in sexual arousal and erection.

COVID-19-associated neurological disease—including peripheral neuropathy, autonomic dysfunction, and small-fiber abnormalities—therefore provides another potential mechanism.

Patients with Long COVID may develop:

orthostatic intolerance;
postural tachycardia;
abnormal sweating;
sensory neuropathy;
pelvic or genital sensory abnormalities;
fatigue;
impaired autonomic cardiovascular regulation; and
sexual dysfunction.

The relationship between autonomic dysfunction and ED has not been adequately quantified, but it is biologically credible.

A patient who develops post-COVID autonomic neuropathy may simultaneously experience impaired genital vasodilation, altered sensory input, abnormal cardiovascular responses, and reduced sexual function.

This is one reason why ED in Long COVID should not necessarily be regarded as an isolated genital disorder.

Endocrine Mechanisms

Testosterone and the hypothalamic-pituitary-gonadal axis are additional potential targets.

Acute severe COVID-19 has been associated in observational studies with reductions in circulating testosterone and alterations in gonadotropins. Systemic inflammation, critical illness, obesity, metabolic disease, sleep disruption, and hypothalamic-pituitary suppression can all contribute.

Low testosterone can reduce:

libido;
spontaneous erections;
nocturnal erections;
erectile responsiveness;
energy;
muscle mass; and
psychological well-being.

Importantly, however, testosterone deficiency should not be assumed solely from ED after COVID-19.

A morning total testosterone concentration should generally be obtained when symptoms suggest hypogonadism, with repeat measurement and additional testing when appropriate before a diagnosis is made.

Testosterone replacement is not a general treatment for COVID-associated ED.

Cardiovascular and Metabolic Mechanisms

COVID-19 can adversely affect cardiovascular health through myocarditis, vascular dysfunction, thrombosis, deconditioning, autonomic abnormalities, and metabolic deterioration.

Because ED is strongly associated with cardiovascular disease, the appearance of new ED after COVID-19 should sometimes be regarded as a cardiovascular warning signal rather than merely a sexual complaint.

The penis is a vascular organ. Penile arteries are smaller than many coronary arteries; consequently, vascular dysfunction may become clinically apparent through ED before more overt cardiovascular disease manifests.

Accordingly, a man who develops new ED after COVID-19—particularly when he has hypertension, diabetes, dyslipidemia, obesity, renal disease, smoking exposure, or exercise intolerance—should receive an appropriate cardiovascular risk assessment.

Psychological and Psychiatric Mechanisms

Psychological mechanisms are neither trivial nor mutually exclusive with organic disease.

COVID-19 and Long COVID can be associated with:

depression;
anxiety;
post-traumatic stress;
sleep disruption;
chronic fatigue;
social isolation;
relationship stress;
fear of reinfection;
impaired self-image; and
reduced physical capacity.

These factors can reduce libido, interfere with sexual arousal, and impair erectile reliability.

Psychological and organic mechanisms frequently reinforce one another.

For example:

vascular impairment → failed erection → performance anxiety → sympathetic activation → further erectile failure.

Consequently, the presence of a psychological component does not demonstrate that ED is “all in the patient’s head.”

Medication-Associated Erectile Dysfunction

Another important consideration is treatment rather than infection itself.

Several medications commonly used by patients with cardiovascular disease, hypertension, depression, anxiety, and other chronic illnesses can adversely affect sexual function.

Potential contributors include selected:

antihypertensive agents;
beta-blockers;
antidepressants;
antipsychotics;
opioids;
antiandrogenic medications; and
other drugs affecting hormonal or autonomic pathways.

Medication review is therefore an essential component of evaluation.

A patient may develop ED after COVID-19 because COVID caused vascular injury; because a medication was initiated during or after the illness; because underlying diabetes or cardiovascular disease progressed; or because several mechanisms operate simultaneously.

Diagnostic Evaluation

A structured evaluation should distinguish among vascular, neurogenic, endocrine, medication-related, psychological, and mixed ED.

Medical history

The clinician should determine:

erectile function before COVID-19;
timing of onset relative to infection;
severity of acute COVID-19;
persistence or fluctuation;
libido;
morning erections;
nocturnal erections;
ejaculation;
orgasm;
genital sensation;
urinary symptoms;
pelvic pain;
autonomic symptoms;
medications;
diabetes;
hypertension;
cardiovascular disease;
renal disease;
smoking;
alcohol use;
depression and anxiety; and
sleep quality.

The temporal relationship is informative but does not itself establish causation.

Physical examination

Evaluation should include cardiovascular, genital, neurological, vascular, and endocrine assessment as clinically appropriate.

Laboratory assessment

Depending upon the clinical situation, reasonable testing may include:

fasting glucose;
HbA1c;
lipid profile;
morning total testosterone;
repeat testosterone when indicated;
thyroid function;
prolactin in selected patients;
complete blood count;
renal and hepatic function; and
additional endocrine testing guided by symptoms.

Specialized testing

When initial treatment fails or the diagnosis is uncertain, penile duplex Doppler ultrasonography can assess arterial inflow and veno-occlusive function.

Patients with prominent autonomic or neurological manifestations may warrant neurological or autonomic evaluation.

Treatment

Treatment should not focus exclusively on the penis.

The optimal strategy is to identify and treat the physiological abnormalities contributing to ED while providing direct erectile therapy.

Lifestyle and cardiovascular risk reduction

Weight management, smoking cessation, regular physical activity appropriate to the patient’s physiological limitations, optimization of blood pressure and glycemic control, treatment of dyslipidemia, and adequate sleep are fundamental.

In patients with Long COVID and post-exertional malaise, exercise recommendations must be individualized. Aggressive exercise prescriptions can worsen symptoms in susceptible patients.

Phosphodiesterase-5 inhibitors

Phosphodiesterase type-5 inhibitors (PDE5 inhibitors) remain the principal first-line pharmacological therapy for most men with ED.

The principal agents include:

sildenafil;
tadalafil;
vardenafil; and
avanafil.

They inhibit degradation of cGMP and thereby amplify the NO-mediated erectile pathway.

The Fifth International Consultation on Sexual Medicine specifically recommends PDE5 inhibitors for men with ED in the setting of inflammatory conditions and sexual Long COVID, although the direct evidence base specific to COVID-associated ED remains limited.

Important contraindication

PDE5 inhibitors must not be combined with nitrate medications, because the combination can cause dangerous hypotension.

Patients taking multiple cardiovascular medications or with unstable cardiovascular disease require individualized medical assessment before treatment.

Vacuum erection devices

Vacuum erection devices mechanically draw blood into the corpora cavernosa and can be effective when oral therapy is inadequate or contraindicated.

They are particularly useful when the principal problem is vascular insufficiency.

Intracavernosal therapy

Intracavernosal injection therapy with agents such as alprostadil, or combination preparations prescribed by specialists, can produce erections independently of intact neural initiation.

This makes such therapy particularly useful for severe vasculogenic or neurogenic ED.

Intraurethral alprostadil

Intraurethral therapy provides another nonoral option, although efficacy is generally lower than intracavernosal therapy.

Penile prosthesis

For severe, persistent, treatment-refractory ED, implantation of a penile prosthesis provides a highly effective definitive treatment.

This is generally reserved for men in whom less invasive approaches have failed or are unacceptable.

Testosterone Replacement

Testosterone deserves particular attention because hypogonadism has been proposed as a component of post-COVID sexual dysfunction.

Testosterone replacement should not be prescribed simply because ED followed COVID-19.

Appropriate treatment generally requires compatible symptoms and consistently low testosterone measurements, followed by evaluation for the cause of androgen deficiency.

When true hypogonadism is present, testosterone treatment can improve libido and may improve erectile responsiveness. However, testosterone is not a substitute for PDE5 inhibitors in men whose primary disorder is vascular ED with normal androgen status.

Psychological and Relationship Treatment

Psychosexual counseling should not be regarded as an admission that ED is psychological.

Patients with persistent physical symptoms may develop secondary performance anxiety, depression, or relationship distress. Cognitive-behavioral therapy, couples counseling, sex therapy, and treatment of depression or anxiety can therefore be valuable components of comprehensive care.

In many patients, successful treatment requires simultaneous correction of the organic and psychological components.

Does Treating Endothelial Dysfunction Treat the ED?

This remains an important research question.

Because endothelial dysfunction is central to both COVID-19 vascular pathology and conventional ED, therapies that improve endothelial health might theoretically improve post-COVID erectile function.

Potential strategies include:

cardiovascular risk-factor modification;
physical activity when tolerated;
weight reduction;
diabetes control;
lipid control;
blood-pressure management;
smoking cessation;
PDE5 inhibition; and
treatment of underlying cardiovascular disease.

However, evidence specifically demonstrating that reversal of a COVID-specific endothelial abnormality restores erectile function remains limited.

Claims that anticoagulation, fibrinolysis, supplements, or experimental “microclot” treatments reliably restore post-COVID erectile function are not presently supported by adequate randomized evidence.

Prognosis

The prognosis of post-COVID ED is incompletely characterized.

Several patterns appear possible.

Transient dysfunction

Some men experience ED during acute illness or shortly afterward and subsequently recover as systemic inflammation, fatigue, psychological stress, and vascular dysfunction improve.

Persistent but treatable dysfunction

Others develop prolonged ED that remains responsive to conventional therapies such as PDE5 inhibitors.

Persistent organic dysfunction

A subset may develop persistent vascular, neurological, autonomic, or endocrine abnormalities requiring longer-term treatment.

Progressive disease revealing pre-existing vascular pathology

In some patients, COVID-19 may not create an entirely new disease but instead reveal or accelerate pre-existing endothelial dysfunction.

This possibility is especially important in older men and those with diabetes, hypertension, obesity, cardiovascular disease, dyslipidemia, or chronic kidney disease.

The 2026 systematic review’s pooled estimate of 21% ED among Long COVID populations demonstrates that the problem can be clinically substantial, but it does not establish that 21% of infected men will develop permanent COVID-induced impotence.

Is Erectile Dysfunction a Biomarker of Long COVID?

An intriguing hypothesis is that ED may serve as a marker of broader systemic disease.

The rationale is compelling: the penis is highly sensitive to endothelial dysfunction, while Long COVID may involve vascular, autonomic, inflammatory, metabolic, and neurological abnormalities.

The 2022 review proposed that ED could potentially serve as a biomarker of systemic complications in Long COVID.

The Fifth International Consultation on Sexual Medicine subsequently suggested that sexual Long COVID may become a clinical biomarker of underlying complications of Long COVID and recommended that sexual health be proactively addressed in affected patients.

This remains a hypothesis rather than an established clinical biomarker.

Nevertheless, new ED after COVID-19 should not automatically be dismissed as an isolated sexual complaint.

Limitations of the Current Evidence

Several limitations constrain interpretation of the literature.

First, much of the evidence remains observational.

Second, ED is frequently self-reported rather than objectively measured.

Third, men with severe COVID-19 often possess multiple pre-existing ED risk factors.

Fourth, medications, hospitalization, psychological stress, and reduced physical activity can independently impair sexual function.

Fifth, the histopathological penile study involved only two COVID-positive patients.

Sixth, studies of Long COVID frequently involve specialty-clinic populations that may overrepresent severe or persistent disease.

Finally, there is limited longitudinal evidence demonstrating whether specific COVID-associated biological abnormalities directly predict persistent ED.

These limitations do not invalidate the association; they define the questions that future research must answer.

Future Research

The field would benefit from prospective studies enrolling men before or immediately after SARS-CoV-2 infection and following them longitudinally with:

validated erectile-function instruments;
penile Doppler measurements;
endothelial biomarkers;
testosterone and gonadotropin measurements;
autonomic testing;
neurological assessments;
metabolic profiling;
cardiovascular imaging when indicated;
inflammatory and immune markers; and
standardized Long COVID phenotyping.

Ideally, such studies would compare infected men with carefully matched uninfected controls and would distinguish acute COVID, post-acute recovery, and persistent Long COVID.

Penile tissue studies, while necessarily limited by ethical and practical considerations, may also clarify whether viral RNA or antigen persistence occurs in erectile tissue and whether such findings correlate with endothelial injury.

Randomized trials are particularly needed to determine whether specific therapies produce greater benefit in COVID-associated ED than in conventional vasculogenic ED.

Conclusion

The accumulated evidence supports an association between SARS-CoV-2 infection, Long COVID, and erectile dysfunction, while the magnitude and mechanisms of the association remain incompletely defined.

The biological rationale is unusually strong. Erectile function depends upon endothelial integrity, nitric-oxide signaling, vascular perfusion, autonomic and peripheral neural function, adequate androgenic signaling, cardiometabolic health, and psychological well-being. COVID-19 can perturb every one of these systems.

The most compelling evidence concerns vascular dysfunction. SARS-CoV-2 has been associated with endothelial injury and impaired NO signaling, while a small histopathological investigation identified SARS-CoV-2 RNA and reduced eNOS expression in penile tissue from men who had experienced COVID-19 and subsequently developed severe ED.

Epidemiological evidence is also increasingly consistent. A large electronic-health-record analysis found an association between COVID-19 and newly diagnosed ED, and a 2026 systematic review and meta-analysis estimated a pooled ED frequency of approximately 21% among patients with Long COVID.

Yet causality must be interpreted carefully. COVID-19-associated ED is probably not a single disease entity. Rather, it appears to encompass a heterogeneous group of vascular, neurogenic, autonomic, endocrine, psychological, medication-related, and mixed disorders.

Clinically, new ED after COVID-19 deserves more attention than it has traditionally received. It may be the first conspicuous manifestation of endothelial or cardiovascular dysfunction, a component of autonomic or peripheral neurological disease, a manifestation of hypogonadism, or a consequence of the psychological and physical burden of Long COVID.

Fortunately, the appearance of ED after COVID-19 does not imply inevitable permanent impotence. Established treatments—including PDE5 inhibitors, vacuum devices, intracavernosal therapy, psychosexual interventions, and, when necessary, penile prosthesis implantation—remain effective therapeutic options. Underlying cardiovascular, metabolic, endocrine, neurological, and psychological abnormalities should be treated simultaneously.

The principal clinical message is therefore straightforward:

Erectile dysfunction after COVID-19 should be regarded neither as an inevitable consequence of infection nor as an unrelated coincidence. In an appropriate patient, it is a potentially meaningful manifestation of post-COVID vascular, neurological, autonomic, endocrine, and systemic disease that warrants systematic evaluation and evidence-based treatment.

References and Footnotes

1. Sansone A, Mollaioli D, Limoncin E, et al. The Sexual Long COVID (SLC): Erectile Dysfunction as a Biomarker of Systemic Complications for COVID-19 Long Haulers. Sex Med Rev. 2022;10(2):271–285.

2. Kresch E, Rao AR, Ramasamy R. COVID-19 Endothelial Dysfunction Can Cause Erectile Dysfunction: Histopathological, Immunohistochemical, and Ultrastructural Study of the Human Penis. World J Mens Health. 2021. The investigators detected SARS-CoV-2 RNA in penile tissue from two previously infected men and found reduced eNOS expression compared with controls.

3. Kresch E, et al. SARS-CoV-2 endothelial dysfunction and erectile dysfunction: histopathological and ultrastructural investigation. The study provides evidence compatible with penile endothelial involvement but is severely limited by its sample size and observational design.

4. La Vignera S, Cannarella R, Condorelli RA, et al. Impact of COVID-19 on erectile function. Review of potential vascular, endocrine, inflammatory, metabolic, and psychological mechanisms underlying COVID-associated ED.

5. COVID-19 Infection Is Associated With New Onset Erectile Dysfunction: Insights From a National Registry. Sex Med. 2022;10(1):100478. The analysis used a large U.S. electronic-health-record network and propensity matching for major ED risk factors.

6. Unveiling the genitourinary phenotype of long COVID: a systematic review and meta-analysis. International Urology and Nephrology. 2026. Nine studies comprising 2,332 participants were included; pooled ED frequency was estimated at 21% (95% CI 16–28%).

7. Fifth International Consultation on Sexual Medicine. Infection, inflammation, and sexual function in male and female patients. Sex Med Rev. 2025. The consensus recommendations recognize sexual dysfunction, including ED, as a potential component of Long COVID and recommend PDE5 inhibitors for men with ED when appropriate.

8. The detection of SARS-CoV-2 RNA in penile tissue should not be interpreted as proof of persistent productive viral infection. PCR positivity establishes the presence of viral genetic material, not necessarily replication-competent virus.

9. The association between COVID-19 and ED should be distinguished from causation. Diabetes, obesity, hypertension, cardiovascular disease, dyslipidemia, chronic kidney disease, medication exposure, depression, anxiety, and age are independent causes or contributors to ED and are also associated with increased risk of severe COVID-19.

10. PDE5 inhibitors are contraindicated with organic nitrates because of the potential for profound hypotension. Cardiovascular fitness for sexual activity should be considered before treatment in men with significant cardiovascular disease.

11. Testosterone therapy should be reserved for men with appropriately documented hypogonadism and compatible symptoms. Empirical testosterone administration solely because ED developed after COVID-19 is not evidence-based.

12. Evidence for COVID-specific treatments such as anticoagulation, fibrinolysis, immunotherapy, supplements, or experimental therapies for ED remains insufficient to recommend routine use specifically for post-COVID erectile dysfunction.

13. The current evidence supports a model of heterogeneous “sexual Long COVID” rather than a single pathophysiological disorder. Vascular, endothelial, autonomic, neurological, endocrine, psychological, metabolic, and medication-related mechanisms may coexist in the same patient.